Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Recommendation of “Moderate Buy” from Analysts

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has been assigned an average rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and ten have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $343.83.

Several analysts have recently weighed in on MDGL shares. Wolfe Research assumed coverage on Madrigal Pharmaceuticals in a report on Tuesday, June 11th. They set an “outperform” rating and a $382.00 price target on the stock. Cantor Fitzgerald restated a “neutral” rating on shares of Madrigal Pharmaceuticals in a research report on Tuesday, July 23rd. Citigroup dropped their price target on shares of Madrigal Pharmaceuticals from $382.00 to $371.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. StockNews.com raised shares of Madrigal Pharmaceuticals to a “sell” rating in a research note on Friday, September 20th. Finally, JMP Securities raised their target price on Madrigal Pharmaceuticals from $381.00 to $385.00 and gave the stock a “market outperform” rating in a research report on Tuesday, July 16th.

Insider Buying and Selling

In related news, CEO William John Sibold sold 6,363 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $243.83, for a total transaction of $1,551,490.29. Following the transaction, the chief executive officer now owns 55,887 shares in the company, valued at approximately $13,626,927.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 23.92% of the stock is currently owned by insiders.

Institutional Trading of Madrigal Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Rhenman & Partners Asset Management AB acquired a new stake in Madrigal Pharmaceuticals in the 4th quarter valued at $5,206,000. Norges Bank acquired a new position in shares of Madrigal Pharmaceuticals during the fourth quarter valued at about $33,686,000. Paulson & CO. Inc. increased its position in shares of Madrigal Pharmaceuticals by 121.1% during the fourth quarter. Paulson & CO. Inc. now owns 1,105,741 shares of the biopharmaceutical company’s stock worth $255,846,000 after acquiring an additional 605,741 shares in the last quarter. Rheos Capital Works Inc. bought a new stake in shares of Madrigal Pharmaceuticals during the first quarter worth about $29,432,000. Finally, AMI Asset Management Corp raised its holdings in shares of Madrigal Pharmaceuticals by 101.5% in the 1st quarter. AMI Asset Management Corp now owns 9,618 shares of the biopharmaceutical company’s stock worth $2,568,000 after acquiring an additional 4,845 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Madrigal Pharmaceuticals Stock Performance

Shares of Madrigal Pharmaceuticals stock opened at $212.43 on Friday. The company’s 50 day moving average price is $249.50 and its two-hundred day moving average price is $248.83. The firm has a market capitalization of $4.61 billion, a P/E ratio of -9.20 and a beta of -0.43. Madrigal Pharmaceuticals has a fifty-two week low of $119.76 and a fifty-two week high of $299.98. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.72 and a quick ratio of 8.67.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($7.10) earnings per share for the quarter, beating the consensus estimate of ($7.55) by $0.45. The firm had revenue of $14.64 million for the quarter, compared to analyst estimates of $4.25 million. During the same period last year, the business earned ($4.69) EPS. The company’s revenue was up 146280.0% compared to the same quarter last year. On average, equities analysts forecast that Madrigal Pharmaceuticals will post -27.67 earnings per share for the current fiscal year.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.